Trials / Withdrawn
WithdrawnNCT01061372
12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
Randomized Double-Blind, 12-Week Study Of Pregabalin In Subjects With Restless Legs Syndrome
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess efficacy and safety of pregabalin in treating moderate to severe Restless Legs Syndrome in comparison to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks |
| DRUG | pregabalin | pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks |
| DRUG | pregabalin | pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2010-02-03
- Last updated
- 2021-01-22
Source: ClinicalTrials.gov record NCT01061372. Inclusion in this directory is not an endorsement.